RNAZ NASDAQ
TransCode Therapeutics, Inc.
1W: -0.6%
1M: -2.3%
3M: -66.3%
YTD: -77.4%
1Y: -87.5%
3Y: -100.0%
5Y: -100.0%
$1.67
-0.04 (-2.08%)
Weekly Expected Move ±12.2%
$1
$2
$2
$2
$2
Credit Risk of going bust: higher than 91% of companies Debt: 27.0% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.18 (down 89%), TransCode Therapeutics, Inc. would be worth roughly what it owes.
Total debt $652K against a stock market value of $1.8M.
Distance to default 1.50 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $652K (short-term plus half of long-term), stock volatility 95.6%; Altman Z'' 7.18. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $652K against a stock market value of $1.8M.
Distance to default 1.50 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $652K (short-term plus half of long-term), stock volatility 95.6%; Altman Z'' 7.18. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
11 relationships11
As Filer
counterparties named
0
As Counterparty
mentioned by others
5
Rel. Types
2023-04-14
Earliest Filing
2025-10-08
Latest Filing
investor: 3
partner: 3
acquirer: 2
target: 2
licensee: 1
Counterparties (Filed by RNAZ)
11 relationshipsCompanies named in RNAZ's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| DEFJ, LLC | — | acquirer | Acquired 100% of ABCJ, LLC and invested in Series A and B Preferred Stock | 2025-10-08 | View |
| ABCJ, LLC | — | target | Target company acquired by TransCode Therapeutics, Inc. | 2025-10-08 | View |
| CK Life Sciences Int'l., (Holdings) Inc. | — | investor | Parent company of ABCJ, LLC prior to acquisition | 2025-10-08 | View |
| Equiniti Trust Company, LLC | — | partner | Acted as rights agent for the Contingent Value Rights Agreement | 2025-10-08 | View |
| DEFJ, LLC | — | acquirer | Acquired 100% of ABCJ, LLC and invested in TransCode Therapeutics, Inc. | 2025-10-08 | View |
| ABCJ, LLC | — | target | Target company acquired by TransCode Therapeutics, Inc. | 2025-10-08 | View |
| CK Life Sciences Int'l., (Holdings) Inc. | — | investor | Parent company of ABCJ, LLC prior to the acquisition. | 2025-10-08 | View |
| Equiniti Trust Company, LLC | — | partner | Served as rights agent for the Contingent Value Rights Agreement. | 2025-10-08 | View |
| The General Hospital Corporation | — | licensee | Entered into Second Amendment to Exclusive Patent License Agreement with TransCode Therapeutics, Inc. | 2025-10-03 | View |
| ThinkEquity LLC | — | partner | Placement agent for the registered direct offering of common stock and warrants. | 2025-03-25 | View |
| White Lion Capital, LLC | — | investor | Counterparty to a Common Stock Purchase Agreement for the sale of newly issued shares. | 2023-04-14 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-01 | Material Agreement | Agreement | View |
| 2026-09-28 | Other Events; Exhibits | View | |
| 2026-09-11 | Officer/Director Change; Exhibits | View | |
| 2026-08-03 | Bylaws Amendment; Exhibits | View | |
| 2026-07-20 | Shareholder Vote | View | |
| 2026-07-17 | Bylaws Amendment; Exhibits | View | |
| 2026-07-02 | Other Events | View | |
| 2026-06-18 | Regulation FD; Exhibits | View | |
| 2026-06-03 | Other Events; Exhibits | View | |
| 2026-06-01 | Other Events | View | |
| 2026-05-26 | Delisting Notice | View | |
| 2026-05-22 | Delisting Notice | View | |
| 2026-04-07 | Material Agreement; Financial Obligation; Unregistered Equity Sales; Regulation FD; Exhibits | Agreement | View |
| 2026-03-03 | Unregistered Sales of Equity Securities; Material Modification to Rights of Security Holders; Amendm | View | |
| 2026-02-23 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-02-05 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-01-06 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-12-23 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-22 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-12-11 | Regulation FD Disclosure; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR